Illumina Inc. (ILMN) SVP Charles Dadswell Sells 116 Shares
Illumina Inc. (NASDAQ:ILMN) SVP Charles Dadswell sold 116 shares of the business’s stock in a transaction on Tuesday, October 4th. The stock was sold at an average price of $182.38, for a total value of $21,156.08. Following the completion of the transaction, the senior vice president now directly owns 39,900 shares of the company’s stock, valued at $7,276,962. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Charles Dadswell also recently made the following trade(s):
- On Wednesday, July 27th, Charles Dadswell sold 8,632 shares of Illumina stock. The stock was sold at an average price of $155.00, for a total value of $1,337,960.00.
Shares of Illumina Inc. (NASDAQ:ILMN) opened at 184.49 on Monday. The firm has a market capitalization of $27.05 billion, a PE ratio of 63.18 and a beta of 0.47. The stock’s 50 day moving average price is $174.63 and its 200-day moving average price is $156.32. Illumina Inc. has a 12 month low of $127.10 and a 12 month high of $196.47.
Illumina (NASDAQ:ILMN) last posted its earnings results on Tuesday, July 26th. The life sciences company reported $0.86 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.13. Illumina had a return on equity of 23.69% and a net margin of 18.73%. The company had revenue of $600 million for the quarter, compared to analyst estimates of $31.91 million. During the same period last year, the company earned $0.80 earnings per share. The business’s revenue was up 11.3% compared to the same quarter last year. On average, equities analysts anticipate that Illumina Inc. will post $3.53 earnings per share for the current fiscal year.
A number of equities analysts have recently weighed in on the company. Canaccord Genuity set a $165.00 price target on Illumina and gave the stock a “hold” rating in a report on Friday. Vetr upgraded Illumina from a “sell” rating to a “buy” rating and set a $198.61 target price for the company in a research note on Monday, October 3rd. Citigroup Inc. upped their target price on Illumina from $175.00 to $190.00 and gave the company a “buy” rating in a research note on Monday, September 12th. Zacks Investment Research upgraded Illumina from a “hold” rating to a “buy” rating and set a $190.00 target price for the company in a research note on Friday, August 26th. Finally, CL King lowered Illumina from a “buy” rating to a “neutral” rating in a research note on Monday, August 22nd. One analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and eleven have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $166.03.
A number of institutional investors have recently bought and sold shares of the stock. Aviva PLC raised its position in Illumina by 2.4% in the first quarter. Aviva PLC now owns 75,222 shares of the life sciences company’s stock valued at $12,194,000 after buying an additional 1,749 shares during the period. Menta Capital LLC acquired a new stake in shares of Illumina during the first quarter valued at about $603,000. CapWealth Advisors LLC increased its stake in shares of Illumina by 9.1% in the first quarter. CapWealth Advisors LLC now owns 14,906 shares of the life sciences company’s stock valued at $2,416,000 after buying an additional 1,240 shares in the last quarter. NN Investment Partners Holdings N.V. acquired a new stake in shares of Illumina during the first quarter valued at about $403,000. Finally, BlackRock Japan Co. Ltd increased its stake in shares of Illumina by 1.7% in the first quarter. BlackRock Japan Co. Ltd now owns 181,033 shares of the life sciences company’s stock valued at $29,347,000 after buying an additional 3,001 shares in the last quarter. Institutional investors own 95.22% of the company’s stock.
Illumina Company Profile
Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.